SEARCH:   Advanced

Blood, 15 March 2004, Vol. 103, No. 6, pp. 2162-2169. Prepublished online as a Blood First Edition Paper on November 20, 2003; DOI 10.1182/blood-2003-04-1091. This Article Full Text (PDF) All Versions of this Article: 2003-04-1091v1 103/6/2162    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Rothenfusser, S. Articles by Hartmann, G. Search for Related Content PubMed PubMed Citation Articles by Rothenfusser, S. Articles by Hartmann, G. Social Bookmarking                   What's this? Submitted April 8, 2003 Accepted October 17, 2003 CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro Simon Rothenfusser, Veit Hornung, Maha Ayyoub, Stefanie Britsch, Andreas Towarowski, Anne Krug, Anja Sarris, Norbert Lubenow, Daniel Speiser, Stefan Endres, and Gunther Hartmann* Division of Clinical Pharmacology, Department of Internal Medicine, University of Munich, Munich, Germany Division of Clinical Onco-immunology, Centre Hospitalier Universitaire Vaudois (CHUV), Ludwig Institute for Cancer Research, Lausanne, Switzerland Institute of Immunology and Transfusion Medicine, University of Greifswald, Greifswald, Germany * Corresponding author; email: ghartmann{at}lrz.uni-muenchen.de. Two distinct types of CpG ODN have been identified that differ in their capacity to stimulate antigen presenting cells: CpG-A induce high amounts of IFN-/- in plasmacytoid dendritic cells (PDC), while CpG-B induce PDC maturation and are potent activators of B cells, but stimulate only small amounts of IFN-/-. Here we examined the ability of these CpG ODN to enhance peptide specific CD8+ T cell responses in human PBMC. The frequency of influenza matrix specific "memory" CD8+ T cells was increased by both types of CpG ODN, while the frequency of Melan-A specific "naive" CD8+ T cells increased upon stimulation with CpG-B but not with CpG-A. The presence of PDC in PBMC was required for this CpG ODN-mediated effect. The expanded cells were cytotoxic and produced IFN- upon peptide restimulation. Soluble factors induced by CpG-A but not CpG-B increased the granzyme-B content and cytotoxicity of established CD8+ T cell clones both of which was IFN-/- dependent. In conclusion, CpG-B seems to be superior for priming of CD8+ T cell responses, while CpG-A selectively enhances memory CD8+ T cell responses and induce cytotoxicity. These results demonstrate distinct functional properties of CpG-A and CpG-B with regard to CD8 T cells. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J.-E. Park, Y.-I. Kim, and A.-K. Yi Protein Kinase D1: A New Component in TLR9 Signaling J. Immunol., August 1, 2008; 181(3): 2044 - 2055. [Abstract] [Full Text] [PDF] A. Malaspina, S. Moir, A. C. DiPoto, J. Ho, W. Wang, G. Roby, M. A. O'Shea, and A. S. Fauci CpG Oligonucleotides Enhance Proliferative and Effector Responses of B Cells in HIV-Infected Individuals J. Immunol., July 15, 2008; 181(2): 1199 - 1206. [Abstract] [Full Text] [PDF] B. G. Molenkamp, B. J.R. Sluijter, P. A.M. van Leeuwen, S. J.A.M. Santegoets, S. Meijer, P. G.J.T.B. Wijnands, J. B.A.G. Haanen, A. J.M. van den Eertwegh, R. J. Scheper, and T. D. de Gruijl Local Administration of PF-3512676 CpG-B Instigates Tumor-Specific CD8+ T-Cell Reactivity in Melanoma Patients Clin. Cancer Res., July 15, 2008; 14(14): 4532 - 4542. [Abstract] [Full Text] [PDF] D. Valmori, N. E. Souleimanian, V. Tosello, N. Bhardwaj, S. Adams, D. O'Neill, A. Pavlick, J. B. Escalon, C. M. Cruz, A. Angiulli, et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming PNAS, May 22, 2007; 104(21): 8947 - 8952. [Abstract] [Full Text] [PDF] A. Faith, E. Peek, J. McDonald, Z. Urry, D. F. Richards, C. Tan, G. Santis, and C. Hawrylowicz Plasmacytoid Dendritic Cells from Human Lung Cancer Draining Lymph Nodes Induce Tc1 Responses Am. J. Respir. Cell Mol. Biol., March 1, 2007; 36(3): 360 - 367. [Abstract] [Full Text] [PDF] M. Pashenkov, G. Goess, C. Wagner, M. Hormann, T. Jandl, A. Moser, C. M. Britten, J. Smolle, S. Koller, C. Mauch, et al. Phase II Trial of a Toll-Like Receptor 9-Activating Oligonucleotide in Patients With Metastatic Melanoma J. Clin. Oncol., December 20, 2006; 24(36): 5716 - 5724. [Abstract] [Full Text] [PDF] C. Casati, C. Camisaschi, F. Rini, F. Arienti, L. Rivoltini, F. Triebel, G. Parmiani, and C. Castelli Soluble Human LAG-3 Molecule Amplifies the In vitro Generation of Type 1 Tumor-Specific Immunity. Cancer Res., April 15, 2006; 66(8): 4450 - 4460. [Abstract] [Full Text] [PDF] M. Kerkmann, L. T. Costa, C. Richter, S. Rothenfusser, J. Battiany, V. Hornung, J. Johnson, S. Englert, T. Ketterer, W. Heckl, et al. Spontaneous Formation of Nucleic Acid-based Nanoparticles Is Responsible for High Interferon-{alpha} Induction by CpG-A in Plasmacytoid Dendritic Cells J. Biol. Chem., March 4, 2005; 280(9): 8086 - 8093. [Abstract] [Full Text] [PDF] B. Jahrsdorfer, L. Muhlenhoff, S. E. Blackwell, M. Wagner, H. Poeck, E. Hartmann, R. Jox, T. Giese, B. Emmerich, S. Endres, et al. B-Cell Lymphomas Differ in their Responsiveness to CpG Oligodeoxynucleotides Clin. Cancer Res., February 15, 2005; 11(4): 1490 - 1499. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020